CDMO– tag –
-
Lonza Expands US Manufacturing with New Spray Drying Facility; Samsung Biologics Secures $262M European CDMO Deal
Endpoints News Switzerland, South Korea, USA Overview Lonza announced a significant expansion of its U.S. manufacturing capabilities with a new commercial spray drying facility in Bend, Oregon, projected for completion by 2029 and creati... -
Lonza, Sartorius, and FUJIFILM Diosynth Bolster Biopharmaceutical Manufacturing Capacity, Highlighting Single-Use Technology as Key
SNS Insider Unknown Overview This article highlights the biopharmaceutical manufacturing capacity expansions by Lonza Group, Sartorius, and FUJIFILM Diosynth Biotechnologies, as noted in the "Biopharmaceutical Fermentation Market" report... -
Northway Biotech Unveils €61M Personalized Medicine & CAR-T Manufacturing Plant in Lithuania, Accelerating European CGT Hub Formation
European Biotechnology Lithuania Overview CDMO Northway Biotech has invested €61 million to open a state-of-the-art cell therapy and personalized medicine center in Vilnius, Lithuania. The facility is actively pursuing GMP manufacturing ... -
Lonza to Build Large-Scale Commercial Spray-Drying Facility in Bend, Oregon, Enhancing US Drug Manufacturing Capacity by 2029
24/7 BIOPHARMA USA Overview Lonza, a leading CDMO, has announced plans for a large-scale commercial spray-drying facility in Bend, Oregon. This investment solidifies Lonza's position as a premier CDMO provider for commercial-scale spray-... -
Samsung Biologics Secures $262M Manufacturing Contract with European Pharma Amid Peptide Expansion and CDMO Capacity Growth
BioProcess International South Korea Overview On September 10, 2026, Samsung Biologics announced a $262 million manufacturing agreement with an undisclosed European pharmaceutical company. This substantial contract will further accelerat... -
Evonik Breaks Ground on Biotechnology Expansion in Slovakia, Strengthening European Pharmaceutical Manufacturing Hub
Evonik Germany Overview On September 14, 2026, Evonik initiated construction for a significant biotechnology manufacturing expansion at its Fermín site in Slovakia. This investment aims to bolster the company's production capacity for ac... -
Lonza to Build New Spray-Drying Facility in Oregon, US, Bolstering CDMO Capabilities in Particle Engineering for Enhanced Bioavailability
SWI swissinfo.ch Switzerland Overview Lonza, a leading Swiss CDMO, announced on September 10, 2026, plans to construct a new state-of-the-art manufacturing facility in Bend, Oregon, specialized in spray-drying technology. Expected to be ... -
WuXi XDC Out-Licenses WuXiTecan-2 Linker-Payload Technology to Ona Therapeutics to Accelerate ADC Development
PR Newswire China Overview WuXi XDC announced the out-licensing of its innovative WuXiTecan-2 linker-payload technology platform to Ona Therapeutics, a Spanish biotechnology company, to advance novel Antibody-Drug Conjugate (ADC) researc... -
Shilpa Biologicals Opens GMP Facility for ADC Manufacturing in India’s Pharmacit
Biospectrum Jobs India Overview Shilpa Biologicals has inaugurated a new GMP-compliant facility in Pharmacit, India, dedicated to the manufacturing of Antibody-Drug Conjugates (ADCs). This state-of-the-art facility will provide end-to-en... -
Northway Biotech Opens Landmark €61M CDMO in Lithuania, Set to Drive European Cell and Personalized Medicine Manufacturing Scale-Up
chemanager-online.com Lithuania Overview Northway Biotech has launched a state-of-the-art €61 million Contract Development and Manufacturing Organization (CDMO) in Vilnius, Lithuania, specifically designed for cell therapy and personaliz...
